daratumumab
E852348
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Daratumumab | 1 |
| daratumumab canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292090 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: daratumumab Context triple: [CD38, targetOf, daratumumab]
-
A.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: daratumumab Target entity description: Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
A.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Statements (59)
| Predicate | Object |
|---|---|
| instanceOf |
CD38-targeting antibody
ⓘ
antineoplastic agent ⓘ immunotherapy drug ⓘ monoclonal antibody ⓘ |
| antibodyType | IgG1 kappa ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | L01FD02 ⓘ |
| bindsTo |
CD38 antigen on plasma cells
ⓘ
linked to:
CD38
|
| canInterfereWith |
blood compatibility testing
ⓘ
indirect antiglobulin test ⓘ |
| coDevelopedBy | Janssen Biotech ⓘ |
| commonAdverseEffect |
anemia
ⓘ
infusion-related reaction ⓘ neutropenia ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| developedBy | Genmab ⓘ |
| eliminationHalfLife | approximately 18 days ⓘ |
| EMAAuthorizationYear | 2016 ⓘ |
| FDAApprovalYear | 2015 ⓘ |
| hasBrandName |
Darzalex
ⓘ
Darzalex Faspro ⓘ
linked to:
Darzalex
|
| indicatedFor |
light chain (AL) amyloidosis
ⓘ
linked to:
light chain amyloidosis
newly diagnosed multiple myeloma in transplant-eligible patients ⓘ newly diagnosed multiple myeloma in transplant-ineligible patients ⓘ refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| isHuman | true ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
induces antibody-dependent cellular phagocytosis ⓘ induces apoptosis via cross-linking ⓘ induces complement-dependent cytotoxicity ⓘ modulates immune suppressor cells in the tumor microenvironment ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| requiresPremedication |
antihistamines
ⓘ
antipyretics ⓘ corticosteroids ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetCellType |
malignant plasma cell
ⓘ
normal plasma cell ⓘ |
| targets | CD38 ⓘ |
| usedFor | multiple myeloma ⓘ |
| usedInCombinationWith |
bortezomib
ⓘ
bortezomib and dexamethasone ⓘ bortezomib and melphalan and prednisone ⓘ carfilzomib ⓘ carfilzomib and dexamethasone ⓘ cyclophosphamide ⓘ cyclophosphamide and bortezomib and dexamethasone ⓘ dexamethasone ⓘ lenalidomide ⓘ lenalidomide and dexamethasone ⓘ melphalan ⓘ pomalidomide ⓘ pomalidomide and dexamethasone ⓘ thalidomide ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: daratumumab Description of subject: Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.